Experimental protection by a luteinizing hormone-releasing hormone agonist of a bone marrow nitrosourea aplasia. Preliminary observations.
D-Tryptophan-6-luteinizing hormone-releasing hormone (D-Trp6-LH-RH) applied from day -8 to day +15 before and after administration of the nitrosourea analog, N,N'-bis[N-(2-chloroethyl)-N-nitrosocarbamoyl]cysteamine (CNCC), favored bone marrow restoration, as independently evaluated by 3 observers in a double-blind fashion.
D000818:Animals; D001835:Body Weight / Q000187:drug effects; D001853:Bone Marrow / Q000187:drug effects*; D001855:Bone Marrow Diseases / Q000139:chemically induced / Q000517:prevention & control*; D004311:Double-Blind Method; D007987:Gonadotropin-Releasing Hormone / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006412:Hematopoietic Stem Cells / Q000187:drug effects; D008186:Luteolytic Agents / Q000627:therapeutic use*; D008297:Male; D051379:Mice; D009607:Nitrosourea Compounds; D017329:Triptorelin Pamoate
D008186:Luteolytic Agents; D009607:Nitrosourea Compounds; D017329:Triptorelin Pamoate; D007987:Gonadotropin-Releasing Hormone; C033713:N,N'-bis((2-chloroethyl)nitrosocarbamoyl)cystamine